Developer docs
API playgroundTry for free, no card

Search company profiles

Capstan Medical

Full company profile

uuid0000ipr

Namestring
Capstan Medical
Legal namestring
Capstan Medical
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Capstan Medical is a privately held medical device company founded in 2020 in Santa Cruz, California, developing the Capstan Compass System — a robotic-enabled platform that combines surgical robotics, AI-enhanced imaging, and catheter-based technology to replace mitral and tricuspid heart valves while the heart is still beating. The company addresses an unmet clinical need in structural heart disease: despite a large patient population, no FDA-approved transcatheter mitral or tricuspid valve replacement options currently exist, and over 80% of patients are excluded from existing investigational mitral valve replacement options due to anatomical constraints. The platform pairs a compact, anatomy-friendly valve implant with a robotic delivery system intended to enable precise placement through a catheter, positioning Capstan as a less invasive alternative to open-heart surgery with shorter recovery times.

The company was founded by Dan Wallace, a former NASA flight controller serving as CTO, and CEO Maggie Nixon, who have worked together since 2000. Capstan operates from Santa Cruz (headquarters in the Wrigley Building) with engineering offices in Portola Valley and West Menlo Park, California. The company is pre-revenue and exclusively in clinical investigation mode; first-in-human robotic catheter mitral valve replacements were completed in March 2025 across sites in Chile, New Zealand, and Brazil, with US FDA submission targeted to support a 2028 commercial launch. The next-generation robotic system is planned for 2026 and is designed to be less than half the size of the first generation with 40% fewer components.

Capstan has raised $110 million across a $31.4M Series B (August 2023, led by Eclipse with Intuitive Ventures and Puma Venture Capital) and a $110M Series C (December 2024, led by Eclipse with Intuitive Ventures). The cap table includes strategic backing from Intuitive Ventures, the investment arm of Intuitive Surgical (valued at $200B), and personal investment from Dr. Fred Moll, cofounder of Intuitive Surgical, who has deployed approximately $100M of personal capital across roughly 15 next-generation surgical robotics startups. The intended go-to-market is enterprise hospital sales of capital equipment (robotic delivery platform) plus per-procedure revenue from implants and consumables, targeting cardiac centers and underserved populations including those with rheumatic heart disease in developing markets.

Short descriptiontext

Capstan Medical develops the Capstan Compass System, a robotic-enabled catheter-based platform with AI-enhanced imaging for minimally invasive mitral and tricuspid heart valve replacement. The pre-revenue company is running first-in-human clinical trials across four countries, targeting FDA submission for a 2028 US launch.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSanta Cruz, United States
HQ citystring
Santa Cruz
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
structural heart devices, catheter-based valves, robotic heart surgery, mitral valve replacement, tricuspid valve technology
Industry2 codes
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Structural Heart Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Heart Valve Implants
TypeHardware Sales
Description

Sale of next-generation mitral and tricuspid valve replacement implants for catheter-based procedures. The company is developing comprehensive valve solutions as part of its structural heart platform.

medtechdive.com
2Robotic Delivery Platform
TypeHardware Sales
Description

Sale of surgical robotic systems and capital equipment for catheter-based structural heart procedures. The next-gen system features significantly smaller footprint with 40% fewer components.

medicaldesignandoutsourcing.com
3Procedural Accessories and Consumables
TypeHardware Sales
Description

Associated delivery systems and accessories for valve implantation procedures performed using the Capstan Compass System.

capstanmedical.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Capstan Compass System
Description

A platform designed to treat mitral and tricuspid valve disease through a catheter while the heart is still beating, combining surgical robotics, AI enhanced imaging with a catheter-based approach

capstanmedical.com
Core offering1 text field

Capstan Medical develops the Capstan Compass System, a robotic-enabled platform that combines surgical robotics, AI-enhanced imaging, and catheter-based technology to treat mitral and tricuspid valve disease through a catheter while the heart is still beating. The platform is paired with a compact mitral valve replacement implant designed to address anatomical constraints that currently exclude over 80% of patients from existing investigational mitral valve replacement options. Products are currently exclusively for clinical investigation use and not for sale in any country.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Over 80% of patients are currently excluded from existing mitral valve replacement options due to anatomical constraints that the Capstan platform addresses
+1 more record
Product overview1 text field

Capstan Medical offers the Capstan Compass System, a unified platform that combines surgical robotics with AI-enhanced imaging and catheter-based technology for the treatment of mitral and tricuspid valve disease. The platform enables minimally invasive heart valve replacement while the heart is still beating, providing a less invasive alternative to traditional open-heart surgery with improved patient outcomes and shorter recovery times.

Product and service1 record
1Capstan Compass System
CategoryStructural heart medical device platform (robotic-assisted transcatheter valve replacement)
Description

A robotic-enabled platform that combines surgical robotics, AI-enhanced imaging, and catheter-based technology to treat mitral and tricuspid valve disease through a catheter while the heart is still beating, offering a less invasive alternative to open-heart surgery. It is paired with a compact mitral valve replacement implant designed for patients anatomically excluded from existing investigational mitral valve replacement options.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Emerging surgical robotics company backed by Dr. Fred Moll and other surgical-robotics investors. Comparable to Capstan through overlapping investor base and parallel effort to bring next-gen surgical robotics into operating rooms.

TypeEmerging player
Description

Public surgical-robotics company developing a minimally invasive robotic platform. Comparable to Capstan as a next-generation surgical robotics peer, though focused on abdominal procedures rather than structural heart.

TypeDirect peer
Description

The dominant structural-heart medtech with the Sapien TAVR platform and Pascal transcatheter mitral repair system. Most directly comparable to Capstan as a transcatheter valve competitor targeting the same mitral/tricuspid patient pool, with vastly greater clinical, regulatory, and commercial resources.

4Abbott
TypeDirect peer
Description

Major structural-heart player with MitraClip and the Tendyne transcatheter mitral replacement program. Competes head-to-head with Capstan in transcatheter mitral and tricuspid therapies and brings established hospital sales channels and trial infrastructure.

TypeDirect peer
Description

Global medtech with structural-heart programs including transcatheter mitral and tricuspid devices (e.g., Intrepid). Comparable to Capstan as a competing structural-heart therapy developer with deep hospital relationships and global clinical-trial capability.

TypeBroad incumbent
Description

Diversified medtech with structural-heart and transcatheter valve programs (e.g., ACURATE neo, mitral/tricuspid efforts). Overlaps with Capstan in transcatheter valve therapy but competes through a much broader cardiology portfolio.

TypeEmerging player
Description

Pre-commercial/early-commercial transcatheter valve developer focused on aortic regurgitation and structural-heart indications. Comparable to Capstan as a similarly sized, clinical-stage transcatheter valve company pursuing FDA pathways.

TypeEmerging player
Description

Clinical-stage developer of transcatheter mitral valve technologies (AltaValve). Comparable to Capstan in the mitral-specific transcatheter replacement space and at a similar pre-commercial stage.

TypeEmerging player
Description

Developer of transcatheter mitral valve replacement devices (Saturn). Closely comparable to Capstan as a small, clinical-stage company focused on the same TMVR opportunity.

TypeBroad incumbent
Description

Global leader in surgical robotics (Da Vinci). Not a direct competitor in structural heart but a key strategic reference point and investor (via Intuitive Ventures) for Capstan's robotic architecture and commercial playbook.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Capstan Medical

Structural Heart Medical Devicescapstanmedical.com

Capstan Medical develops the Capstan Compass System, a robotic-enabled catheter-based platform with AI-enhanced imaging for minimally invasive mitral and tricuspid heart valve replacement. The pre-revenue company is running first-in-human clinical trials across four countries, targeting FDA submission for a 2028 US launch.

What Capstan Medical does

Capstan Medical is a privately held medical device company founded in 2020 in Santa Cruz, California, developing the Capstan Compass System — a robotic-enabled platform that combines surgical robotics, AI-enhanced imaging, and catheter-based technology to replace mitral and tricuspid heart valves while the heart is still beating. The company addresses an unmet clinical need in structural heart disease: despite a large patient population, no FDA-approved transcatheter mitral or tricuspid valve replacement options currently exist, and over 80% of patients are excluded from existing investigational mitral valve replacement options due to anatomical constraints. The platform pairs a compact, anatomy-friendly valve implant with a robotic delivery system intended to enable precise placement through a catheter, positioning Capstan as a less invasive alternative to open-heart surgery with shorter recovery times.

The company was founded by Dan Wallace, a former NASA flight controller serving as CTO, and CEO Maggie Nixon, who have worked together since 2000. Capstan operates from Santa Cruz (headquarters in the Wrigley Building) with engineering offices in Portola Valley and West Menlo Park, California. The company is pre-revenue and exclusively in clinical investigation mode; first-in-human robotic catheter mitral valve replacements were completed in March 2025 across sites in Chile, New Zealand, and Brazil, with US FDA submission targeted to support a 2028 commercial launch. The next-generation robotic system is planned for 2026 and is designed to be less than half the size of the first generation with 40% fewer components.

Capstan has raised $110 million across a $31.4M Series B (August 2023, led by Eclipse with Intuitive Ventures and Puma Venture Capital) and a $110M Series C (December 2024, led by Eclipse with Intuitive Ventures). The cap table includes strategic backing from Intuitive Ventures, the investment arm of Intuitive Surgical (valued at $200B), and personal investment from Dr. Fred Moll, cofounder of Intuitive Surgical, who has deployed approximately $100M of personal capital across roughly 15 next-generation surgical robotics startups. The intended go-to-market is enterprise hospital sales of capital equipment (robotic delivery platform) plus per-procedure revenue from implants and consumables, targeting cardiac centers and underserved populations including those with rheumatic heart disease in developing markets.

Capstan Medical firmographics

Firmographics
Name
Capstan Medical
Legal name
Capstan Medical
Website
https://capstanmedical.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
101–250 employees
Short description
Capstan Medical develops the Capstan Compass System, a robotic-enabled catheter-based platform with AI-enhanced imaging for minimally invasive mitral and tricuspid heart valve replacement. The pre-revenue company is running first-in-human clinical trials across four countries, targeting FDA submission for a 2028 US launch.
Ownership category
akta.pro rank

Capstan Medical industry classification

Industry
Product category
Structural Heart Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Structural heart devices
  • Catheter-based valves
  • Robotic heart surgery
  • Mitral valve replacement
  • Tricuspid valve technology

Where Capstan Medical is headquartered

Location

Headquarters

HQ city
Santa Cruz
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Capstan Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Heart Valve Implants: Sale of next-generation mitral and tricuspid valve replacement implants for catheter-based procedures. The company is developing comprehensive valve solutions as part of its structural heart platform.
  2. Robotic Delivery Platform: Sale of surgical robotic systems and capital equipment for catheter-based structural heart procedures. The next-gen system features significantly smaller footprint with 40% fewer components.
  3. Procedural Accessories and Consumables: Associated delivery systems and accessories for valve implantation procedures performed using the Capstan Compass System.

Go-to-market motion1 record

Marketing channels5 records

Capstan Medical product offering

Product offering

Core offering

Capstan Medical develops the Capstan Compass System, a robotic-enabled platform that combines surgical robotics, AI-enhanced imaging, and catheter-based technology to treat mitral and tricuspid valve disease through a catheter while the heart is still beating. The platform is paired with a compact mitral valve replacement implant designed to address anatomical constraints that currently exclude over 80% of patients from existing investigational mitral valve replacement options. Products are currently exclusively for clinical investigation use and not for sale in any country.

Product overview

Capstan Medical offers the Capstan Compass System, a unified platform that combines surgical robotics with AI-enhanced imaging and catheter-based technology for the treatment of mitral and tricuspid valve disease. The platform enables minimally invasive heart valve replacement while the heart is still beating, providing a less invasive alternative to traditional open-heart surgery with improved patient outcomes and shorter recovery times.

Differentiator

Problem solved

Functional benefit

Brands

  • Capstan Compass System: A platform designed to treat mitral and tricuspid valve disease through a catheter while the heart is still beating, combining surgical robotics, AI enhanced imaging with a catheter-based approach

Products and services

  • Capstan Compass System A robotic-enabled platform that combines surgical robotics, AI-enhanced imaging, and catheter-based technology to treat mitral and tricuspid valve disease through a catheter while the heart is still beating, offering a less invasive alternative to open-heart surgery. It is paired with a compact mitral valve replacement implant designed for patients anatomically excluded from existing investigational mitral valve replacement options.

Quantifiable outcome

  • Over 80% of patients are currently excluded from existing mitral valve replacement options due to anatomical constraints that the Capstan platform addresses
  • +1 more outcomes

Companies that use Capstan Medical

Customer profile

Segments3 records

Ideal customer profiles1 record

Capstan Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Capstan Medical partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Capstan Medical competitors and assessment

Company assessment

Emerging players

  • Moon Surgical: Emerging surgical robotics company backed by Dr. Fred Moll and other surgical-robotics investors. Comparable to Capstan through overlapping investor base and parallel effort to bring next-gen surgical robotics into operating rooms.
  • Vicarious Surgical: Public surgical-robotics company developing a minimally invasive robotic platform. Comparable to Capstan as a next-generation surgical robotics peer, though focused on abdominal procedures rather than structural heart.
  • JenaValve Technology: Pre-commercial/early-commercial transcatheter valve developer focused on aortic regurgitation and structural-heart indications. Comparable to Capstan as a similarly sized, clinical-stage transcatheter valve company pursuing FDA pathways.
  • 4C Medical Technologies: Clinical-stage developer of transcatheter mitral valve technologies (AltaValve). Comparable to Capstan in the mitral-specific transcatheter replacement space and at a similar pre-commercial stage.
  • InnovHeart: Developer of transcatheter mitral valve replacement devices (Saturn). Closely comparable to Capstan as a small, clinical-stage company focused on the same TMVR opportunity.

Direct peers

  • Edwards Lifesciences: The dominant structural-heart medtech with the Sapien TAVR platform and Pascal transcatheter mitral repair system. Most directly comparable to Capstan as a transcatheter valve competitor targeting the same mitral/tricuspid patient pool, with vastly greater clinical, regulatory, and commercial resources.
  • Abbott: Major structural-heart player with MitraClip and the Tendyne transcatheter mitral replacement program. Competes head-to-head with Capstan in transcatheter mitral and tricuspid therapies and brings established hospital sales channels and trial infrastructure.
  • Medtronic: Global medtech with structural-heart programs including transcatheter mitral and tricuspid devices (e.g., Intrepid). Comparable to Capstan as a competing structural-heart therapy developer with deep hospital relationships and global clinical-trial capability.

Broad incumbents

  • Boston Scientific: Diversified medtech with structural-heart and transcatheter valve programs (e.g., ACURATE neo, mitral/tricuspid efforts). Overlaps with Capstan in transcatheter valve therapy but competes through a much broader cardiology portfolio.
  • Intuitive Surgical: Global leader in surgical robotics (Da Vinci). Not a direct competitor in structural heart but a key strategic reference point and investor (via Intuitive Ventures) for Capstan's robotic architecture and commercial playbook.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Capstan Medical social profiles

Digital presence

Capstan Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Capstan Medical leadership team

Management profile

Number of profiles

Profiles11 records

Capstan Medical funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Capstan Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Capstan Medical

What does Capstan Medical do?

Capstan Medical develops the Capstan Compass System, a robotic-enabled platform that combines surgical robotics, AI-enhanced imaging, and catheter-based technology to treat mitral and tricuspid valve disease through a catheter while the heart is still beating. The platform is paired with a compact mitral valve replacement implant designed to address anatomical constraints that currently exclude over 80% of patients from existing investigational mitral valve replacement options. Products are currently exclusively for clinical investigation use and not for sale in any country.

Is Capstan Medical a public or private company?

Capstan Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Capstan Medical founded?

Capstan Medical was founded in 2020. It employs 101 to 250 people.

Where is Capstan Medical based?

Capstan Medical is headquartered in Santa Cruz, United States, in the North America region.

How does Capstan Medical make money?

Three revenue lines are on record. Heart Valve Implants are the primary driver. The others are robotic Delivery Platform and procedural Accessories and Consumables.

Who are Capstan Medical's main competitors?

Emerging players on record are Moon Surgical, Vicarious Surgical, JenaValve Technology, 4C Medical Technologies and InnovHeart. Direct peers are Edwards Lifesciences, Abbott and Medtronic. Broad incumbents are Boston Scientific and Intuitive Surgical.

Does Capstan Medical have an API?

No public API is recorded for Capstan Medical.

What industry is Capstan Medical in?

Capstan Medical's product category is Structural Heart Medical Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms. Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCapstan Medical Completes First U.S. Procedure With Investigational Robotic Mitral Valve Replacement SystemCapstan Medical completed its first U.S. robotic-assisted transcatheter mitral valve replacement on Nov 9 at The Christ Hospital in Cincinnati, Ohio. The procedure was part of an FDA-authorized feasibility study, and the patient was discharged home in stable condition. The system is investigational and not approved for commercial use in the U.S.MedicaldesignandoutsourcingCapstan Medical CEO Maggie Nixon’s career advice, travel tips and how she starts her dayMaggie Nixon, CEO of Capstan Medical, was interviewed about her career path from Stanford to Intuitive and her current role. She advises asking the right questions and using engineering thinking across business functions. She also shares her daily routine and travel tips.MedicaldesignandoutsourcingComing soon: Capstan Medical’s next-gen structural heart robotics systemCapstan Medical, an Intuitive-backed surgical robotics and structural heart startup, plans to bring its second-generation robotic system online in 2026 while continuing clinical trials for its mitral valve replacement implant. The company has expanded its first-in-human procedures beyond Chile and New Zealand to include Brazil, targeting underserved patient populations including those with rheumatic heart disease. The next-gen system features a significantly smaller footprint (less than 50% the size), 40% fewer components, and a custom procedural controller replacing the Xbox controller used in early work.PR NewswireMarshall Mohr Joins Capstan Medical Board of DirectorsCapstan Medical, a developer of robotic-enabled minimally invasive heart valve solutions, announced the appointment of Marshall Mohr to its Board of Directors. Mohr brings experience from Intuitive Surgical, where he served as CFO during a period of exceptional growth in MedTech. The company, which completed pioneering first-in-human robotic-assisted mitral valve replacement procedures in early 2025, previously raised $110 million in an oversubscribed Series C financing in late 2024.ForbesThis Robotic Surgery Legend Is Pouring $100 Million Into Next-Gen Medical StartupsDr. Fred Moll, cofounder of Intuitive Surgical (valued at $200 billion), has invested approximately $100 million of his own funds into about 15 next-generation surgical robotics startups, including publicly traded SS Innovations International (India-based, $1.2B market cap), XCath ($62M valuation), ForSight Robotics ($500M valuation), Neptune Medical ($387M), Capstan Medical ($367M), and Vitestro. His portfolio companies are developing robots for procedures ranging from colonoscopies and cataract surgeries to brain aneurysm treatment and mitral valve replacement, with several leveraging AI and telesurgery capabilities to make advanced surgical care more accessible in both developed and developing markets.MedTech DiveCapstan brings surgical robot to valve replacementCapstan Medical announced it has successfully completed its first human trial using a surgical robot to implant mitral valve replacement devices in two patients, marking a first in structural heart disease treatment. The startup has developed a compact valve and robotic delivery platform that addresses anatomical constraints which currently exclude over 80% of patients from existing investigational mitral valve replacement options. Capstan is backed by $110 million in funding including investment from Intuitive Ventures, and is working toward a pivotal trial with an FDA submission goal of bringing the valve system to market in 2028.Pulse 2.0Capstan Medical: $110 Million (Series C) Raised To Advance Robotic-Enabled Minimally Invasive Solutions For Addressing Heart Valve DiseaseCapstan Medical closed an oversubscribed $110 million Series C led by Eclipse, with participation from existing and new investors. The funding will advance its robotic-enabled minimally invasive solutions for heart valve disease, targeting over 7 million U.S. patients. The company plans expanded clinical and development work leading to upcoming pivotal trials.Business & FinancialSurgical Robotics Startup Capstan Medical Raises $110 Million In New Funding Robotics & Automation NewsCapstan Medical raised $110 million in a Series C round led by Eclipse, with participation from existing and new investors. The surgical robotics startup will use the funds to advance its heart valve disease treatment, including upcoming pivotal trials.FinSMEsCapstan Medical Raises $110M in Series C FundingCapstan Medical raised $110M in Series C funding led by Eclipse, with participation from existing investors and new investment from Gideon Strategic Partners. The Santa Cruz-based company will use the funds to advance its robotics technology for heart valve disease. Founded in 2020, it has over 75 employees.MobiHealthNewsCapstan Medical garners $110M for robotic-enabled heart valve repair techCalifornia-based Capstan Medical closed an oversubscribed $110 million Series C funding round led by Eclipse to enhance its robotic-enabled tools for heart valve disease. The funds will help the company advance its healthcare reach, addressing the urgent needs of patients suffering from heart valve disease. The investment reflects a broader interest in innovative healthcare solutions for cardiovascular health.